Highlights:
• Hudson Institute identifies anti-inflammatory properties of idronoxil as consistent with blocking ‘cytokine storm’ believed responsible for many COVID-19 deaths
• Pre-clinical models suggest ability to treat patients with early-stage organ failure andprevent need for intensive care treatment
• NOX will require non-dilutive funding for a proposed clinical trial
• Australian provisional patent application filed• Idronoxil clinic-ready and with high safety profile
• Special oral formulation (NOX-19) to be used• Veyonda® clinical program to continue while meeting social obligation to investigate potential ability to help reduce the mortality rate of COVID-19
For further information, please refer to the attached PDF
Download this document
